CompsDesk · Peer benchmark preview

AbCellera Biologics Inc. vs its sector — the six numbers your board asks for.

Computed from ABCL's own SEC filings (FY2025), benchmarked against ADCT and AGIO. Every figure is deterministic — no estimates, no AI math — and cites the exact filing in the full pack.

6 CORE METRICS · GUARANTEED
Metric ABCL ADCT AGIO Peer med. Pctile
Revenue $75.1M $81.4M $54.0M $67.7M 50th
Revenue growth (YoY) 160.6% 14.9% 48.0% 31.4% 100th
Operating margin -289.0% -149.3% -873.9% -511.6% 50th
Net margin -194.9% -175.3% -764.0% -469.7% 50th
FCF margin -231.7% -173.8% -698.3% -436.1% 50th
Capex % of revenue 56.9% 0.3% 8.0% 4.2% 100th
Gross margin
SG&A % · R&D % · tax rate
Net debt/EBITDA · cash-conversion cycle · buybacks
+ up to 8 extended metrics, trends for every filed year & up to 12 peers in your full board-ready pack — PDF + CSV, every number cited to its filing.
Get ABCL's full pack — $249 → Add your own peers first
↗ Copy link ✉ Forward to your CFO / board

Green/red = better/worse than the peer median where direction is unambiguous. Percentile = share of these peers at or below ABCL's value. The full pack adds up to 12 same-sector peers you choose, up to 8 extended metrics where disclosed, trends for every filed year (up to five), and a provenance table citing every figure to its 10-K. Delivered within one business day; 14-day refund if any figure misstates its cited filing. Informational benchmarking from public SEC data — not investment advice. — Sam, CompsDesk